JP2018538003A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538003A5
JP2018538003A5 JP2018533200A JP2018533200A JP2018538003A5 JP 2018538003 A5 JP2018538003 A5 JP 2018538003A5 JP 2018533200 A JP2018533200 A JP 2018533200A JP 2018533200 A JP2018533200 A JP 2018533200A JP 2018538003 A5 JP2018538003 A5 JP 2018538003A5
Authority
JP
Japan
Prior art keywords
nucleic acid
expression cassette
vector
acid expression
regulatory element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018533200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/082314 external-priority patent/WO2017109039A1/en
Publication of JP2018538003A publication Critical patent/JP2018538003A/ja
Publication of JP2018538003A5 publication Critical patent/JP2018538003A5/ja
Priority to JP2021040766A priority Critical patent/JP7376018B2/ja
Pending legal-status Critical Current

Links

JP2018533200A 2015-12-22 2016-12-22 内皮特異的核酸調節エレメントならびにその方法および使用 Pending JP2018538003A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021040766A JP7376018B2 (ja) 2015-12-22 2021-03-12 内皮特異的核酸調節エレメントならびにその方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/081075 2015-12-22
EP2015081075 2015-12-22
PCT/EP2016/082314 WO2017109039A1 (en) 2015-12-22 2016-12-22 Endothelium-specific nucleic acid regulatory elements and methods and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021040766A Division JP7376018B2 (ja) 2015-12-22 2021-03-12 内皮特異的核酸調節エレメントならびにその方法および使用

Publications (2)

Publication Number Publication Date
JP2018538003A JP2018538003A (ja) 2018-12-27
JP2018538003A5 true JP2018538003A5 (enExample) 2020-02-06

Family

ID=57821918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533200A Pending JP2018538003A (ja) 2015-12-22 2016-12-22 内皮特異的核酸調節エレメントならびにその方法および使用
JP2021040766A Active JP7376018B2 (ja) 2015-12-22 2021-03-12 内皮特異的核酸調節エレメントならびにその方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021040766A Active JP7376018B2 (ja) 2015-12-22 2021-03-12 内皮特異的核酸調節エレメントならびにその方法および使用

Country Status (6)

Country Link
US (2) US11446375B2 (enExample)
EP (1) EP3393523B9 (enExample)
JP (2) JP2018538003A (enExample)
AU (1) AU2016378480A1 (enExample)
CA (1) CA3009264A1 (enExample)
WO (1) WO2017109039A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700086403A1 (it) * 2017-07-27 2019-01-27 Univ Del Piemonte Orientale Endothelial-specific promoter sequences and uses thereof
JP2022505876A (ja) 2018-10-26 2022-01-14 フリーイェ・ユニヴェルシテイト・ブリュッセル 遺伝子治療を向上させる新しいツール及びその使用
BR112021014373A2 (pt) * 2019-01-24 2021-11-03 Excellgene Sa Métodos para produzir e usar alfa 1-antitripsina (aat) recombinante e composições da mesma
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CN111534541A (zh) * 2020-05-07 2020-08-14 西南大学 一种真核生物CRISPR-Cas9双gRNA载体及构建方法
AU2021321412A1 (en) * 2020-08-05 2023-04-06 Spacecraft Seven, Llc Adeno-associated viral vector for GLUT1 expression and uses thereof
US20220233714A1 (en) * 2021-01-27 2022-07-28 Vanderbilt University Nanogold-dna bioconjugates and methods of use thereof
CN114032239B (zh) * 2021-10-28 2024-06-21 北京美康基免生物科技有限公司 一种组织特异启动子及其应用
EP4368209A1 (en) 2022-11-09 2024-05-15 Vrije Universiteit Brussel Cardiac vascular endothelial cell-derived nucleic acid regulatory elements and methods and use thereof
CN117925624B (zh) * 2024-03-22 2024-05-31 上海凌医生物科技有限公司 一种金属响应调控元件

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656454A (en) * 1994-10-04 1997-08-12 President And Fellows Of Harvard College Endothelial cell-specific enhancer
FR2756570B1 (fr) * 1996-12-03 2002-09-27 Commissariat Energie Atomique Promoteur de la ve-cadherine et ses utilisations
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
ITMI20011138A1 (it) * 2001-05-29 2002-11-29 Uni Di Torino Vettore e metodi di impiego per l'espressione selettiva di geni in siti di angiogenesi in vivo
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
WO2011090684A2 (en) * 2009-12-29 2011-07-28 Cornell University Methods for developing endothelial cells from pluripotent cells and endothelial cells derived
EP2675901B1 (en) 2011-02-14 2018-05-30 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
JP2015109833A (ja) * 2013-11-08 2015-06-18 学校法人慶應義塾 線維芽細胞から血管内皮細胞を製造する方法

Similar Documents

Publication Publication Date Title
JP7248760B2 (ja) 肝特異的核酸調節要素ならびにその方法および用途
Fausther-Bovendo et al. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
TWI904068B (zh) 核酸分子及其用途
Hulot et al. Gene therapy for the treatment of heart failure: promise postponed
KR101253363B1 (ko) 개선된 아데노바이러스 벡터 및 그것의 용도
US12558416B2 (en) Endothelium-specific nucleic acid regulatory elements and methods and use thereof
Matveeva et al. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
CN107427557B (zh) 用于包装和表达变体因子viii以治疗血友病的改良表达组件
JP2008056679A5 (enExample)
Jay et al. Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair
JP2013501038A5 (enExample)
JP2025508677A5 (enExample)
JP2008545406A5 (enExample)
KR20130138245A (ko) 종양분해 아데노바이러스 벡터 및 이와 관련된 방법 및 용도
JP2014527404A5 (enExample)
JP2018537089A5 (enExample)
WO2021259206A1 (zh) 针对sars-cov-2病毒的dna疫苗及其用途
CN100471957C (zh) 用于免疫治疗的腺病毒载体
US20080003236A1 (en) Adenovirus fiber shaft composition and methods of use
CN103266121B (zh) 一种复制子dna疫苗载体及其构建方法与应用
Kazemi et al. Mutagenesis in sequence encoding of human factor VII for gene therapy of hemophilia
JPWO2023171719A5 (enExample)
Aldrich et al. 849. Transduction of Mouse Dendritic Cells Is Enhanced by Repetitive Infection with Self-Complementary Adeno-Associated Virus 6 Combined with Immunostimulatory Ligands
WO2007061053A1 (ja) 筋肉指向性プロモーターとsv40ウイルスプロモーターの混成プロモーター及びそれを含むベクター
Hodges et al. 531. Balloon Catheter-Mediated Hepatic Vein Delivery of a Viral Vector Mitigates Neutralization by Anti-Viral Antibodies and Results in Efficient Transduction of Rabbit Liver